What question did this study set out to answer?

This research aims to compare the drug survival rates of adalimumab and infliximab in patients with hidradenitis suppurativa.

May 16, 2026

Drug Survival of Adalimumab and Infliximab in Hidradenitis Suppurativa

Puntos clave

This research aims to compare the drug survival rates of adalimumab and infliximab in patients with hidradenitis suppurativa.
Data collection on drug survival rates of adalimumab and infliximab in hidradenitis suppurativa patients
Use of patient records to analyze therapeutic outcomes
Results will provide insights on the effectiveness and durability of adalimumab compared to infliximab
Specific numerical data and event rates are not disclosed due to restrictions

Resumen

The authors declare no conflicts of interest. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Me gusta

Guardar